Humana (NYSE:HUM) experienced a 3% price increase last week, which may have been influenced by its recent partnership with Mercy to open new primary care clinics for seniors. This expansion addresses ...

Humana faces significant earnings headwinds due to CMS reforms, star rating downgrades, and potential Medicaid clawbacks.

Humana’s stock performance and market strategies continue to be closely monitored by investors and analysts, with particular attention to how the company navigates industry challenges.

Raymond (NSE:RYMD) James has upgraded Humana’s stock rating from Market Perform to Outperform, setting a new price target of $315, citing the company’s strong performance and favorable drug mix.

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $307.44, ...

In a report released today, David Windley from Jefferies maintained a Hold rating on Humana (HUM – Research Report), with a price target of $244.00. The company’s shares close ...

A return of a former CEO and questions about its Medicare Advantage pricing dominate the outlook for this formerly ...

The S&P 500 slipped less than 0.1% on Thursday, May 22, after the House narrowly passed the Republicans' "big beautiful" tax ...

As the Q1 earnings season wraps, let’s dig into this quarter’s best and worst performers in the health insurance providers ...

Detailed price information for Acadia Pharmaceutica (ACAD-Q) from The Globe and Mail including charting and trades.

Humana Inc. closed 39.15% below its 52-week high of $406.46, which the company reached on July 18th. The stock demonstrated a mixed performance when compared to some of its competitors Monday ...